JENNIFER RUBIN GRANDIS
Medical Practice in Pittsburgh, PA

7662793, Feb 16, 2010

Mar 12, 2003

10/387252

Yukai He - Pittsburgh PA, US
Jennifer R. Grandis - Pittsburgh PA, US
Leaf Huang - Pittsburgh PA, US

University of Pittsburgh of the Commonwealth System of Higher Education - Pittsburgh PA

C07H 21/02, C07H 21/04, A61K 31/70, A01N 43/04

514 44, 536 231, 536 243, 536 2433, 536 245

A nucleic acid is provided comprising an expression cassette which includes transcription control sequences of a member of a class of Pol III-transcribed genes in which no transcribed portion of the Pol III gene is required for transcription of the gene. In the expression cassette, the transcribed 5′ hairpin structure of the Pol III gene is deleted. The transcription control sequences are operably linked to a sequence of an EGFR gene in an antisense orientation suitable for decreasing expression of EGFR in the cell when transcribed. Lastly, a method for decreasing expression of EGFR in cells is provided that includes the step of contacting target cells either parenterally or directly into the tumor or tissue adjacent to the tumor cells with the nucleic acid of the present invention.

7960360, Jun 14, 2011

Nov 13, 2007

11/939018

Jennifer Rubin Grandis - Pittsburgh PA, US
Sufi Mary Thomas - Cheswick PA, US
Danith H. Ly - Pittsburgh PA, US

A01N 43/04, A61K 31/70

514 44

A class of antisense agents having a distributed guanidinium peptide nucleic acids (GPNA) backbone which has excellent uptake into mammalian cells, can bind to the target DNA or RNA in a highly sequence specific manner and can resist nucleases and proteases both outside and inside the cell(s) of interest. In one embodiment, either systemic or intratumoral administration of antisense Epidermal Growth Factor Receptor (“EGFR”) GPNA oligonucleotides is believed to downmodulate EGFR levels, thus in turn to reduce head and neck squamous cell carcinoma tumor growth, which has been confirmed to date both in vitro and in vivo.

2011030, Dec 15, 2011

May 13, 2011

13/107344

Jennifer Rubin Grandis - Pittsburgh PA, US
Sufi Mary Thomas - Cheswick PA, US
Danith H. Ly - Pittsburgh PA, US

A61K 38/02, A61P 35/00, C07K 2/00

514 193, 530322

A class of antisense agents having a distributed guanidinium peptide nucleic acids (GPNA) backbone which has excellent uptake into mammalian cells, can bind to the target DNA or RNA in a highly sequence specific manner and can resist nucleases and proteases both outside and inside the cell(s) of interest. In one embodiment, either systemic or intratumoral administration of antisense Epidermal Growth Factor Receptor (“EGFR”) GPNA oligonucleotides is believed to downmodulate EGFR levels, thus in turn to reduce head and neck squamous cell carcinoma tumor growth, which has been confirmed to date both in vitro and in vivo.

2006029, Dec 28, 2006

Jul 22, 2005

11/188248

Jennifer Grandis - Pittsburgh PA, US
Daniel Johnson - Glenshaw PA, US
Paul Leong - Pittsburgh PA, US

A61K 48/00, A61K 33/36, A61K 31/7072, A61K 31/7048, A61K 31/704, A61K 31/525, A61K 31/675, A61K 31/66, A61K 31/337

514044000, 424649000, 514081000, 514700000, 514034000, 514049000, 514027000, 514109000, 514449000, 514283000, 424623000, 514410000, 514251000

A composition is provided that is useful in treating cancers in which STAT3 is activated, such as squamous cell carcinomas including squamous cell carcinoma of the head and neck. The composition comprises an effective amount of a STAT3 decoy and a pharmaceutically acceptable carrier. Also provided are methods of treating such cancers and methods of modulating STAT3 transcriptional activation in a cell.

2013017, Jul 4, 2013

Jul 25, 2012

13/557988

Le Cong - Brookline MA, US
Ann Marie Egloff - Pittsburgh PA, US
Levi A. Garraway - Newton MA, US
Jennifer Rubin Grandis - Pittsburgh PA, US
Eric S. Lander - Cambridge MA, US
Nicholas Stransky - Boston MA, US
Aaron D. Tward - Boston MA, US
Feng Zhang - Cambridge MA, US

A61K 38/16, A61K 45/06, A61K 38/46

424 946, 514 193, 435375

The present invention provides methods related to the treatment of head and neck squamous cell carcinoma (HNSCC) and its associated premalignant lesions. In particular, the invention features methods which may specifically target HNSCC-associated genes and alter gene expression to treat or alleviate a symptom of HNSCC, or its related premalignant lesions. These methods may involve decreasing the function of an HNSCC-associated gene with aberrant gain-of-function; or increasing the function of an HNSCC-associated gene with aberrant loss-of-function.

2012028, Nov 15, 2012

Jun 7, 2012

13/491343

Jennifer R. Grandis - Pittsburgh PA, US
Daniel Johnson - Glenshaw PA, US
Danith Ly - Pittsburgh PA, US

Carnegie Melton - Pittsburgh PA
University of Pittsburgh - Of The Commonwealth System of Higher Education - Pittsburgh PA

C07H 21/00, A61K 9/00, A61N 5/10, C07H 21/04, A61P 35/00, A61P 35/02, A61K 31/713, A61K 39/395

424400, 536 231, 514 44 R, 4241331, 600 1

The present invention is based, at least in part, on novel, unimolecular STAT3 oligonucleotide decoys exhibiting increased in vivo stability as compared to previously known decoys which are effective in inhibiting STAT3 when administered systemically. The invention is also based on pharmaceutical compositions comprising these unimolecular decoys, and methods for using these decoys in the treatment of cancer.

6063586, May 16, 2000

Feb 4, 1998

9/018796

Jennifer Rubin Grandis - Pittsburgh PA

Eye & Ear Foundation - Oakmont PA

A61K 39395, G01N 3353

435 723

A cancer prognostic having particular utility in the prognosis of head and neck squamous cell cancer, in which the expression levels of either or both of Transforming Growth Factor Alpha (TGF-. alpha. ) or Epidermal Growth Factor Receptor (EGFR) are assayed directly from a sample of tumor tissue. The expression level once quantitated is normalized as to standard, and the standardized expression level is compared to the prognostic threshold of about 83% of standard for TGF-. alpha. or of about 23% of standard for EGFR, or the corresponding upper threshold of the "low" tertile regardless of how calculated. Virtually all if not all patients demonstrating this low expression level survive at least five years after initial diagnosis, assuming completion of treatment with standard surgical tumor excision and radiation protocols for squamous cell head and neck cancer. Whether an individual patient's expression levels of TGF-. alpha. and EGFR fall inside or outside of this category signifies whether the patient is in a good or poor prognostic category, respectively, which in turn guides appropriate choice of therapy.